References
- Li
YC
Bai
& WZ
Hashikawa
T. The neuroinvasive potential of SARS-CoV2 may play a role in
the respiratory failure of COVID-19 patients.J Med Virol. 2020
Feb 27. doi: 10.1002/jmv.25728.
- Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of host
defense following severe acute respiratory syndrome‐coronavirus
(SARS‐CoV) pulmonary infection of mice. J Immunol . 2004; 173:
4030‐ 4039.
- Zhao
W,
Zhong
Z,
Xie
X,
Yu
Q,
Liu
J Relation Between Chest CT Findings and Clinical Conditions of
Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study .
AJR Am J
Roentgenol. 2020 Mar 3:1-6. doi: 10.2214/AJR.20.22976.
- Huang C, Wang Y, Li X, et al. Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;
395: 497‐ 506.
- Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing
and treating infections by a novel coronavirus responsible for a
pneumonia outbreak originating in Wuhan, China. Microbes Infect.
2020. https://doi.org/10.1016/j.micinf.2020.01.003.
- Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting
coronaviruses into the spotlight. Viruses. 2019; 11: 59.
https://doi.org/10.3390/v11010059
- Lu R, Zhao X, Li J, et al. Genomic characterisation and
epidemiology of 2019 novel coronavirus: implications for virus origins
and receptor binding. Lancet. 2020; 395: 565‐ 574.
- Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition
by novel coronavirus from Wuhan: an analysis based on decade‐long
structural studies of SARS. J Virol . 2020.
https://doi.org/10.1128/JVI.00127‐20
- Yuan Y, Cao D, Zhang Y, et al. Cryo‐EM structures of MERS‐CoV
and SARS‐CoV spike glycoproteins reveal the dynamic receptor binding
domains. Nat Commun. 2017; 8:15092.
- Hulswit RJ, de Haan CA, Bosch BJ. Coronavirus spike protein and
tropism changes. Adv Virus Res. 2016; 96: 29‐ 57.
- Li YC, Bai WZ, Hirano N, Hayashida T, Hashikawa T. Coronavirus
infection of rat dorsal root ganglia: ultrastructural characterization
of viral replication, transfer, and the early response of satellite
cells. Virus Res. 2012; 163: 628‐ 635.
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138
hospitalized patients with 2019 novel coronavirus‐infected pneumonia
in Wuhan, China. JAMA . 2020.
- Khan S, Ali A, Siddique R, Nabi G. Novel coronavirus is putting
the whole world on alert. J Hosp Infect. 2020.
https://doi.org/10.1016/j.jhin.2020.01.019
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507‐
513.
- Li K, Wohlford‐Lenane C, Perlman S, et al. Middle East
respiratory syndrome coronavirus causes multiple organ damage and
lethal disease in mice transgenic for human dipeptidyl peptidase 4. J
Infect Dis. 2016; 213: 712‐ 722.
- Talbot PJ, Ekandé S, Cashman NR, Mounir S, Stewart JN. Neurotropism of
human coronavirus 229E. Adv Exp Med Biol . 1993; 342: 339‐ 346.
- Dubé M, Le Coupanec A, Wong AHM, Rini JM, Desforges M, Talbot PJ.Axonal transport enables neuron‐to‐neuron propagation of human
coronavirus OC43. J Virol. 2018; 92,
https://doi.org/10.1128/JVI.00404‐18
- Zhou X, Huang F, Xu L, et al. Hepatitis E virus infects neurons
and brains. J Infect Dis. 2017; 215(8): 1197‐ 1206.
- Li YC, Bai WZ, Hirano N, et al. Neurotropic virus tracing
suggests a membranous‐coating‐mediated mechanism for transsynaptic
communication. J Comp Neurol. 2013; 521: 203‐ 212.
- Mengeling WL, Boothe AD, Ritchie AE. Characteristics of a
coronavirus (strain 67N) of pigs. Am J Vet Res. 1972; 33(2): 297‐
308.
- Andries K, Pensaert MB. Immunofluorescence studies on the
pathogenesis of hemagglutinating encephalomyelitis virus infection in
pigs after oronasal inoculation. Am J Vet Res. 1980; 41(9): 1372‐
1378.
- To KF, Lo AW. Exploring the pathogenesis of severe acute
respiratory syndrome (SARS): the tissue distribution of the
coronavirus (SARS‐CoV) and its putative receptor,
angiotensin‐converting enzyme 2 (ACE2). J Pathol. 2004; 203: 740‐
743.
- Tang JW, To KF, Lo AW, Sung JJ, Ng HK, Chan PK. Quantitative
temporal‐spatial distribution of severe acute respiratory
syndrome‐associated coronavirus (SARS‐CoV) in post‐mortem tissues. J
Med Virol. 2007; 79: 1245‐ 1253
- George
PM,
Wells
AU. Pirfenidone for the treatment of idiopathic pulmonary
fibrosis. Expert
Rev Clin Pharmacol. 2017 May;10(5):483-491. doi:
10.1080/17512433.2017.1295846. Epub 2017 Mar 7.
- Lancaster
LH,
de
Andrade JA et al. Pirfenidone safety and adverse event management in
idiopathic pulmonary fibrosis. Eur Respir Rev. 2017 Dec 6;26(146).
pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31.
- Chung
MP,
Park
MS et al. Safety and Efficacy of Pirfenidone in Advanced
Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing
Surveillance Study in Korean Patients.Adv Ther. 2020
Apr 15. doi: 10.1007/s12325-020-01328-8. [Epub ahead of print]